If the supernatant plasma is used the red cells will be issued as packed cells. If, as in the case of our own preparation, most of the supernatant is returned to the red cells these are issued as reconstituted blood.
Although the method for producing cryoprecipitate is simple enough for it to be made in hospital laboratories it is, obviously, more economical if it is made at blood transfusion centres. Since the first stage of preparing cryoprecipitate involves making fresh-frozen plasma, there is no reason why the development of decentralized production of factor-VIII-cryoprecipitate by blood transfusion centres should interfere with any major programmes of blood fractionation.
Provided that both programmes are developed together, none of the effort, time and money expended on the production of cryoprecipitate will be wastedand patients will get better treatment very much sooner than if we await the products of a new fractionation plant.
Meanwhile, let us hope that the interest already shown by a number of blood transfusion centres in the preparation of cryoprecipitate will spread throughout the country so that adequate supplies of this form of factor VIII concentrate will soon become available to all haemophilia centres. The simple technique developed by Dr Judith Pool for the production of a concentrate of factor VIII, the so-called cryoglobulin methodhas been described in detail by Dr Dormandy. The purpose of the present paper is to show why the more sophisticated methods of plasma fractionation are still necessary. The advantages of cryoprecipitate are its availability and usually high concentration. It is often useful to be able to administer a dose by syringe although one should keep in mind that reactions in the patient might be more difficult to control if a dose is administered rapidly and that the more concentrated the material the more one wastes in unavoidable handling losses. But the option of choosing to administer by syringe should be available to the clinician. This does not necessarily mean that the preparation of cryoprecipitate in a multiplicity of centres is the best long term national policy.
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If, as I believe, a centralized fractionation procedure could supply a factor VIII concentrate with all the desirable criteria, what should these be? First one should be able to rely on its potency. This implies it should have been previously assayed by a reproducible method and should be stable on storage. Its potency should be high enough to permit injection by syringe if clinically desirable. It should be readily and completely soluble and conform to accepted tests for sterility and general toxicity and as far as possible be free from side-effects.
Economy in the use of blood demands that as much as possible of the components should be utilized. If a patient needs only red cells, we usually supply him with plasma as well as red cells and may be deluding ourselves if we regard that plasma as 'used'. There is no doubt that concentrated red cells could be given to many more patients than at present, and the plasma diverted to other clinical uses.
If sufficient plant and staff were available, the supernatant from cryoprecipitate could be fractionated in a similar manner to whole plasma, providing all the usual products with the possible exception of fibrinogen. It would also permit the Section ofMedicine preparation of adequate supplies of factor IX concentrate. But it would then be more rational to provide the factor VIII concentrate from the same central source using the same staff and equipment.
The coagulation factors are present in only trace amounts in plasma, probably only one or two milligrams per litre. Nevertheless, some general principles of protein fractionation are illustrated by the problems encountered in the preparation of a therapeutic concentrate of factor IX. The terms 'concentration', 'purification' and 'yield' used in connexion with fractionation procedures are defined as follows:
Concentration is the ratio of activity per unit volume in the product and the activity per unit volume in the starting material.
Purification is the ratio of activity per unit weight of protein in the product and the activity per unit weight of protein in the starting material.
Yield is calculated by expressing the total amount of activity in the product as a percentage of the total amount of activity in the starting material.
The varying rates of destruction of the coagulation factors after infusion and the varying loss which seems to occur instantaneously from the circulation to a large extent govern the minimum concentration acceptable for a therapeutic preparation. As an approximation we expect the factor IX level of a Christmas disease patient weighing 70 kg to increase by 10% of average normal per 1,000 units' of infused factor IX. So, to reach 50 % of average normal by infusing not more than 500 ml of concentrate, this preparation must have 10 times the factor IX concentration of normal plasma. If the yield of the process is 25 %, then the concentrate must be dissolved in onefortieth of the volume of plasma from which it is derived. To allow for starting from 'bank' plasma, with its higher dilution than laboratory normal plasma, the final solution must be one-fiftieth of the volume of the starting plasma.
The biochemical properties offactors IX, X and VIl are so closely similar to prothrombin that these factors are usually referred to as the 'prothrombin complex'. It would be impractical to try to separate them for clinical purposes and a single preparation can be used for the treatment of congenital defects of any of these factors or for the combined defects associated with liver disease. ' One unit is the activity in 1 0 ml of average normal plasma as defined by Biggs & Macfarlane (1966) All the methods of preparing factor IX concentrates rely on the property of the prothrombin complex of being readily adsorbed on to common adsorbents. But for most of these, citrate is an eluent with the corollary that they will not work in plasma containing citrate anticoagulant. The only adsorbent of the traditional variety which will work in the presence of citrate is aluminium hydroxide, although in the last few years some progress has been made using diethyl aminoethyl cellulose. Recovery from aluminium hydroxide is poor and it is difficult to reach the required concentration of factor IX, especially since any salts used must be suitable for intravenous injection or must be removed. In order to use calcium phosphate as an adsorbent in whole plasma, citrate must not be present. Plasma anticoagulated with ethylene diamine tetra acetic acid (EDTA) is not suitable for the preparation of factor VIII so two lots of special blood must be collectedone for factor VlII and the other for factor IX, as is done in Paris by Professor Soulier's group (Blatrix & Soulier 1959 , Soulier et al. 1962 . Their method, which is shown in Fig 1 gives a yield of about 25 % of the factor IX of the original plasma. This procedure is unlikely to be within the scope of the usual blood bank.
It was impractical for us to start with special plasma in this way. The ether process of Kekwick & Mackay (1954) is used in England at present for the production of factor VIII, y-globulin and albumin. It was the residue from thisthe socalled G. precipitatewhich provided the largest source of factor IX readily available to us.
It is comparatively simple to adsorb the active fraction on tricalcium phosphate and elute with citrate. There are then several practical problems. This fraction contains most of the lipoproteins of plasma, which interfere with sterilization by filtration. This was overcome by denaturation of the lipoproteins by freezing in the presence of ether so as to permit their separation as a gelatinous interfacial layer after centrifugation of the thawed mixture. Residual ether must be removed from the aqueous layer and the citrate concentration must be lowered to a level tolerable for intravenous infusion; dialysis accomplishes both these requirements simultaneously. prothrombin to thrombin and the possibility of producing a mixture which could be lethal. It is for this reason that we test every dose immediately prior to injection for the possible development of coagulant activity. To assist in preventing the activation of the prothrombin complex heparin is added during the preparative process.
The full procedure used in Oxford for the preparation of factor IX is outlined in Fig 2. Our final preparation is at present more pure but less concentrated than that made in Paris. Some of the points discussed above are illustrated in Table  1 which shows the assays and purification of a small experimental batch of factor IX concentrate made from the residue following an alcohol fractionation of plasma. This enables the clinician to give a dose equivalent to 5 litres of plasma in a volume of 500 ml. The purification is nearly 700-fold and the recovery of factor IX is 26%.
I have dealt at some length with the technical problems attendant on the preparation of a factor IX concentrate in order to show why, with our present knowledge of its biochemistry, it seems to me to be unlikely that a method of preparation will be found suitable for carrying out in hospital blood banks as is the cryoprecipitate method for factor VIII, and I hope I have done something to show why there is still need for centralized large-scale fractionation of plasma for the preparation of therapeutic materials for the treatment of coagulation disorders, which should in the long run provide the clinician with bottles of readily soluble and standardized factor VIII and factor IX concentrates.
